Therefore, the purpose of this study was to further explore data from the TONIC trial using predictive modeling to test ALT as a predictor of histologic progression versus improvement of pediatric NAFLD over time. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.